NEW YORK (Reuters Health) – The glucagon-like peptide 1 analog taspoglutide administered subcutaneously once weekly improves glycemic control and reduces body weight in drug-naive patients with type 2…
NEW YORK (Reuters Health) – Most domains of health-related quality of life in iron-deficient patients with chronic heart failure improve significantly after 4 weeks of treatment with intravenous…
NEW YORK (Reuters Health) – If lifestyle changes are not enough to control type 2 diabetes, metformin should be the first oral agent added to treatment, according to…
NEW YORK (Reuters Health) – For patients with acute lung injury on mechanical ventilation, restricting the amount of enteral nutrition provided does not reduce the number of days…
NEW YORK (Reuters Health) – Early, aggressive use of azathioprine is associated with reduced surgery rates in patients with Crohn’s disease, researchers from Hungary report in the January…
NEW YORK (Reuters Health) – Patients with type 2 diabetes who don’t have retinopathy at baseline have a relatively low risk of developing eye complications during 5 to…
NEW YORK (Reuters Health) – Dual rather than mono antiplatelet therapy started soon after ischemic stroke reduces the risk of recurrence without a significant increase in risk of…
NEW YORK (Reuters Health) – Hyperprolactinemia is a relatively common cause of secondary amenorrhea in young women with menstruation irregularities, Korean researchers report in a December 19th on-line…
NEW YORK (Reuters Health) – Muscle relaxants don’t ease the pain of rheumatoid arthritis (RA), and only topical capsaicin among studied neuromodulators offers some relief, according to two…